A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates
M Pino, T Abid, S Pereira Ribeiro, VV Edara… - Science …, 2021 - science.org
Ongoing severe acute respiratory syndrome coronavirus–2 (SARS-CoV-2) vaccine
development is focused on identifying stable, cost-effective, and accessible candidates for …
development is focused on identifying stable, cost-effective, and accessible candidates for …
[HTML][HTML] COVID-19 and cancer comorbidity: therapeutic opportunities and challenges
AS Pathania, P Prathipati, BAA Abdul, S Chava… - Theranostics, 2021 - ncbi.nlm.nih.gov
Abstract The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory …
SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity
The protective effect of neutralizing antibodies in SARS-CoV-2 infected individuals is not yet
well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody …
well defined. To address this issue, we have analyzed the kinetics of neutralizing antibody …
Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins
Molecular mimicry between viral antigens and host proteins can produce cross-reacting
antibodies leading to autoimmunity. The coronavirus SARS-CoV-2 causes COVID-19, a …
antibodies leading to autoimmunity. The coronavirus SARS-CoV-2 causes COVID-19, a …
Immunologic testing for SARS-CoV-2 infection from the antigen perspective
D Li, J Li - Journal of clinical microbiology, 2021 - Am Soc Microbiol
ABSTRACT Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally as a severe …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally as a severe …
Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods
Neutralizing antibodies targeting the receptor-binding domain (RBD) of the SARS-CoV-2
spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into …
spike (S) block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry into …
[HTML][HTML] Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity
Abstract Evaluation of potential immunity against the novel severe acute respiratory
syndrome (SARS) coronavirus that emerged in 2019 (SARS-CoV-2) is essential for health …
syndrome (SARS) coronavirus that emerged in 2019 (SARS-CoV-2) is essential for health …
Fast, accurate, point-of-care COVID-19 pandemic diagnosis enabled through advanced lab-on-chip optical biosensors: Opportunities and challenges
The sudden rise of the worldwide severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) pandemic in early 2020 has called into drastic action measures to perform instant …
CoV-2) pandemic in early 2020 has called into drastic action measures to perform instant …
Rapid, point-of-care scFv-SERS assay for femtogram level detection of SARS-CoV-2
D Antoine, M Mohammadi, M Vitt, JM Dickie… - ACS …, 2022 - ACS Publications
Rapid, sensitive, on-site identification of SARS-CoV-2 infections is an important tool in the
control and management of COVID-19. We have developed a surface-enhanced Raman …
control and management of COVID-19. We have developed a surface-enhanced Raman …
Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection
The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) has led to an unprecedented effort toward the development of an effective …
(SARS-CoV-2) has led to an unprecedented effort toward the development of an effective …